This text discusses non-metastatic colon cancer and the importance of timely adjuvant chemotherapy after surgery. Factors affecting the risk of recurrence include MSI status, tumor stage, number of lymph nodes analyzed, and genomic profile. The MOSAIC study compared FOLFOX4 and LV5FU2 adjuvant chemotherapy in stage II and III patients, with no survival benefit seen in stage II patients after 10 years.